Click on image to view larger version.

Figure 6 (A) Shows the effect of aspirin (160 mg every day for 7 days) on plasma levels of neutrophil-activating peptide (NAP)-2 in 12 healthy control subjects. Baseline level is set to 100% for each individual. (B) Shows plasma levels of NAP-2 in coronary artery disease patients before and after 6 months of therapy with simvastatin (20 mg every day, n = 21) or atorvastatin (80 mg every day, n = 14), with similar effect in both treatment groups. (B) Shows pooled data from both treatment groups (means ± SEM). (C) Shows the effect of ortho-hydroxy atorvastatin (AT; 10 µmol/l) on the gene expression of NAP-2 in peripheral blood mononuclear cells from 5 healthy control subjects after culturing for 20 h (mean ± SEM). (D) Shows the effect of AT (10 µmol/l) on SFLLRN-stimulated (100 µmol/l) release of NAP-2 in platelet-rich plasma (incubated for 90 min) from 6 healthy control subjects. *p < 0.05 and **p < 0.01 versus unstimulated; #p < 0.05 versus SFLLRN-stimulated platelets. The Wilcoxon signed rank test (simple comparisonwise p values) was used for statistical comparisons.